Moderna Inc

NASDAQ:MRNAUnited States

Today

Show headlines and story abstract

• Sector Update: Health Care Stocks Rise Late Afternoon, from 1 hour ago by MT Newswires

  1 hour ago by MT Newswires
  Companies Mentioned: MRNA, AZN, PINC, BNOX
  03:59 PM EST, 11/05/2024 (MT Newswires) -- Health care stocks rose late Tuesday afternoon with the NYSE Health Care Index up 0.4% and the Health Care Select Sector SPDR Fund (XLV) adding 0.7%. The iShares Biotechnology ETF (IBB) climbed 1.4%. In cor...

• Sector Update: Health Care Stocks Rise Tuesday Afternoon, from 3 hours ago by MT Newswires

  3 hours ago by MT Newswires
  Companies Mentioned: VRTX, MRNA, AZN
  02:17 PM EST, 11/05/2024 (MT Newswires) -- Health care stocks rose Tuesday afternoon with the NYSE Health Care Index up 0.4% and the Health Care Select Sector SPDR Fund (XLV) adding 0.7%. The iShares Biotechnology ETF (IBB) climbed 1.1%. In corporat...

• Market Chatter: Bancel Steps Down as Moderna Sales Chief, Keeps CEO Post, from 4 hours ago by MT Newswires

  4 hours ago by MT Newswires
  Companies Mentioned: MRNA
  01:00 PM EST, 11/05/2024 (MT Newswires) -- Moderna (MRNA) Chief Executive Stephane Bancel is stepping down as chief commercial officer but will remain CEO of the company, Bloomberg reported Tuesday, citing a person familiar with the matter. Moderna ...

• --Moderna's Bancel Steps Down as Sales Chief, Keeps CEO Post, Bloomberg Reports, from 4 hours ago by MT Newswires

  4 hours ago by MT Newswires
  Companies Mentioned: MRNA
  12:58 PM EST, 11/05/2024 (MT Newswires) -- Price: 52.37, Change: -1.17, Percent Change: -2.19 ...

• Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024, from 8 hours ago by PR Newswire

  8 hours ago by PR Newswire
  Companies Mentioned: MRNA, CARM

  Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors

  Carisma Therapeutics Inc.(Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming presentation of new pre-clinical data on its anti-GPC3in vivochimeric antigen receptor macrophage and monocyte (together, "CAR-M")therapy for the treatment of hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data will be presented in a poster session at the Society for Immunotherapy of Cancer ("SITC") Annual Meeting in Houston, Texas, on November 8, 2024.